Citigroup Inc Icosavax, Inc. Transaction History

Citigroup Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$5.95 - $15.79 $752,020 - $2 Million	126,390 Added 40.19%	440,892 $6.95 Million
Q3 2023 Nov 09, 2023	SELL	$7.22 - $10.05 $57,312 - $79,776	-7,938 Reduced 2.46%	314,502 $2.44 Million
Q2 2023 Aug 10, 2023	BUY	$4.89 - $10.57 $40,102 - $86,684	8,201 Added 2.61%	322,440 $3.2 Million
Q1 2023 May 11, 2023	SELL	$5.62 - $11.51 $1,039 - $2,129	-185 Reduced 0.06%	314,239 $1.82 Million
Q4 2022 Feb 09, 2023	SELL	$2.32 - $10.97 $12,024 - $56,857	-5,183 Reduced 1.62%	314,424 $2.5 Million
Q3 2022 Nov 10, 2022	BUY	$3.09 - $9.21 $696,102 - $2.07 Million	225,276 Added 238.81%	319,607 $1.01 Million
Q2 2022 Aug 10, 2022	BUY	$5.7 - $10.33 $457,869 - $829,788	80,328 Added 573.65%	94,331 $541,000
Q1 2022 May 12, 2022	BUY	$4.41 - $22.5 $40,492 - $206,595	9,182 Added 190.46%	14,003 $99,000
Q4 2021 Feb 10, 2022	BUY	$21.07 - $34.98 $69,236 - $114,944	3,286 Added 214.07%	4,821 $110,000
Q3 2021 Nov 10, 2021	BUY	$24.85 - $40.25 $38,144 - $61,783	1,535 New	1,535 $45,000

1.37M

Ticker ICVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,885,200
Description
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical tri...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.